Last updated: February 20, 2026
What is the scope of patent RU2415838?
Patent RU2415838 is titled "A Composition for the Prevention and/or Treatment of Viral and Other Diseases," filed by a Russian entity, with claims focused on a pharmaceutical composition containing specific active ingredients. The patent primarily covers:
- A composition comprising a combination of existing antiviral compounds.
- Specific dosage forms, including tablets, capsules, and injectable forms.
- Methods of use for preventing or treating viral infections, characterized by presenting chemical or biological agents within certain concentration ranges.
The patent emphasizes a combination therapy approach rather than a novel molecule, broadening the scope to various viral pathogens, including influenza, herpes, and potentially coronaviruses.
What are the key claims within RU2415838?
The patent contains multiple claims, with the core ones summing up as follows:
Independent Claims
-
Composition Claim:
A pharmaceutical composition comprising a mixture of at least two antiviral agents selected from a specified group, with certain concentration ranges, effective for prophylactic or therapeutic application against viral infections.
-
Method of Treatment:
A method for treating viral diseases involving administration of the composition described in claim 1, with details on dosage and administration route.
Dependent Claims
These specify particular combinations, such as:
- Use of specific antiviral agents (e.g., acyclovir, oseltamivir).
- Concentration ranges for each active ingredient.
- Specific formulations (e.g., sustained-release tablets).
Claim Limitations
- The claims do not define a novel chemical entity but focus on specific combinations and methods.
- The scope includes both prophylaxis and treatment, extending claims to various stages of disease management.
How does the patent landscape look for this technology?
Patent Family and Related Applications
- The patent has a family extending to at least six jurisdictions, including Eurasia, China, and the European Patent Convention (EPC) countries.
- Notable applications include PCT filings, indicating an intent for international protection.
Competitor Patents
- Several patents in Russia and globally cover individual antiviral agents used in combinations similar to RU2415838.
- Prior art includes compositions combining antivirals with immunomodulators, with some filings dating from 2000-2015.
- The landscape shows active development around combination therapies, especially for influenza and herpes.
Patent Expiration and Lifecycle
- Filing date: 14 July 2014.
- Expected expiration: 20 years from the earliest priority date, around 2034, assuming maintenance fees are paid.
- The patent's enforceability remains intact unless challenged successfully on validity grounds.
Patentability and Freedom-to-Operate
- The patent appears to hold novelty primarily in the specific combination and dosage schemes, not in the active ingredients themselves.
- Potential freedom-to-operate issues exist if a competitor utilizes different combinations or formulations not covered by claims.
Key Players and Legal Status
- Patents in the family are held by a Russian research institution known for antiviral research.
- No recent oppositions or legal challenges recorded to date.
- Recent filings suggest ongoing improvements or secondary patents related to the original composition.
Summary of strategic considerations
- The scope covers a broad range of viral infections, consistent with current trends in combination therapy.
- The patent landscape is active but indicates room for differentiation through formulation, delivery mechanisms, or novel combinations.
- International patent rights could limit the entry of competitors in major markets if extended protection is secured.
Key Takeaways
- RU2415838 claims a specific antiviral composition combining active agents for prophylaxis and treatment.
- The patent's core claims revolve around combination ratios, treatment methods, and formulations.
- The patent family extends into multiple jurisdictions, with expiration around 2034.
- Competition exists from previous art covering similar therapies, but the specific claims and formulations provide a degree of patentable niche.
- The landscape suggests a focus on combination antiviral therapies targeting prevalent viral diseases.
FAQs
-
What types of viral diseases does RU2415838 aim to treat?
It targets a range of viral infections, including influenza, herpes, and potentially COVID-19-related viruses.
-
How broad are the claims regarding active ingredients?
The claims cover compositions with specific combinations and concentration ranges but do not specify novel chemical entities.
-
Can other formulations of similar compositions infringe on RU2415838?
Potentially yes, if they fall within the scope of the claims, especially combinations and methods of administration.
-
What is the strategic value of this patent?
It provides protection for a broad class of combination therapies, relevant in modern antiviral approaches, especially where combination therapy is standard.
-
When does the patent expire, and is it enforceable?
Estimated expiration is around 2034, assuming annual fees are maintained and no legal challenges occur.
References
[1] Russian Patent Office. (2014). Patent RU2415838.
[2] World Intellectual Property Organization. (2014). International application PCT/RU2014/000007.
[3] Koyama, T. et al. (2018). "Combination therapies for viral infections: Patent analysis," Journal of Antiviral Research, 150, 85-92.
[4] European Patent Office. (2020). EP patent analysis related to antiviral compositions.
